Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CRMD CorMedix	$13.58 -2.6%	$11.19	$3.61 ▼ $15.38	$945.48M	1.62	1.23 million shs	1.31 million shs
PAHC Phibro Animal Health	$23.96 -2.0%	$21.49	$16.16 ▼ $26.55	$991.05M	0.74	207,130 shs	215,002 shs
SYRE Spyre Therapeutics	$15.08 -0.7%	$14.86	$10.91 ▼ $40.26	$914.98M	2.72	606,606 shs	596,971 shs
TSVT 2seventy bio	$5.00	$4.99	$2.29 ▼ $5.30	$266.15M	1.04	642,396 shs	N/A

2025 Gold Forecast: A Perfect Storm for Demand

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CRMD CorMedix	-2.58%	-6.92%	+6.51%	+25.05%	+213.63%
PAHC Phibro Animal Health	-2.00%	-1.76%	-0.70%	+9.86%	+37.07%
SYRE Spyre Therapeutics	-0.66%	-16.22%	+1.34%	-16.91%	-41.53%
TSVT 2seventy bio	0.00%	0.00%	0.00%	+1.01%	+28.53%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CRMD CorMedix	1.152 of 5 stars	2.6	1.0	0.0	0.0	2.8	0.0	0.6
PAHC Phibro Animal Health	3.8962 of 5 stars	0.8	4.0	2.5	1.1	2.9	3.3	2.5
SYRE Spyre Therapeutics	2.3848 of 5 stars	3.6	1.0	0.0	0.0	2.0	2.5	0.6
TSVT 2seventy bio	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CRMD CorMedix	3.14	Buy	$15.00	10.46% Upside
PAHC Phibro Animal Health	1.67	Reduce	$20.80	-13.19% Downside
SYRE Spyre Therapeutics	3.25	Buy	$53.40	254.11% Upside
TSVT 2seventy bio	2.00	Hold	$5.00	N/A

Current Analyst Ratings Breakdown

Latest TSVT, SYRE, CRMD, and PAHC Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/16/2025	PAHC Phibro Animal Health	BNP Paribas Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold
6/16/2025	PAHC Phibro Animal Health	BNP Paribas Exane Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Underperform ➝ Neutral	$24.00
5/10/2025	TSVT 2seventy bio	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (E+) ➝ Sell (D-)
5/8/2025	PAHC Phibro Animal Health	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Equal Weight ➝ Equal Weight	$20.00 ➝ $21.00
5/7/2025	CRMD CorMedix	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$12.00 ➝ $15.00
5/6/2025	CRMD CorMedix	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$15.00 ➝ $15.00
5/5/2025	SYRE Spyre Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$65.00
4/24/2025	TSVT 2seventy bio	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (D-) ➝ Sell (E+)
4/15/2025	PAHC Phibro Animal Health	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target		$20.00
4/9/2025	CRMD CorMedix	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$12.00 ➝ $12.00
4/8/2025	CRMD CorMedix	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$15.00 ➝ $15.00

(Data available from 6/19/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CRMD CorMedix	$43.47M	21.19	N/A	N/A	$1.40 per share	9.70
PAHC Phibro Animal Health	$1.02B	0.95	$2.07 per share	11.57	$6.34 per share	3.78
SYRE Spyre Therapeutics	$890K	1,021.37	N/A	N/A	$7.04 per share	2.14
TSVT 2seventy bio	$48.37M	5.50	N/A	N/A	$5.04 per share	0.99

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CRMD CorMedix	-$17.93M	$0.22	61.73	14.45	N/A	20.81%	22.57%	17.02%	8/13/2025 (Estimated)
PAHC Phibro Animal Health	$2.42M	$0.78	30.72	11.41	0.46	2.68%	30.51%	6.89%	8/27/2025 (Estimated)
SYRE Spyre Therapeutics	-$208.02M	-$3.77	N/A	N/A	N/A	N/A	-77.46%	-41.06%	8/6/2025 (Estimated)
TSVT 2seventy bio	-$217.57M	-$0.10	N/A	N/A	N/A	-207.25%	-53.65%	-23.67%	8/6/2025 (Estimated)

Latest TSVT, SYRE, CRMD, and PAHC Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/8/2025	Q1 2025	SYRE Spyre Therapeutics	-$0.76	-$0.74	+$0.02	-$0.74	N/A	N/A
5/7/2025	Q3 2025	PAHC Phibro Animal Health	$0.52	$0.63	+$0.11	$0.51	$352.41 million	$347.80 million
5/7/2025	Q1 2025	TSVT 2seventy bio	-$0.10	$0.01	+$0.11	$0.01	$13.96 million	$22.94 million
5/6/2025	Q1 2025	CRMD CorMedix	$0.25	$0.30	+$0.05	$0.30	$38.90 million	$39.08 million
3/25/2025	Q4 2024	CRMD CorMedix	$0.17	$0.22	+$0.05	$0.22	$27.46 million	$30.00 million
3/25/2025	Q4 2024	TSVT 2seventy bio	-$0.23	-$0.31	-$0.08	-$0.37	$12.84 million	$2.93 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CRMD CorMedix	N/A	N/A	N/A	N/A	N/A
PAHC Phibro Animal Health	$0.48	2.00%	N/A	61.54%	N/A
SYRE Spyre Therapeutics	N/A	N/A	N/A	N/A	N/A
TSVT 2seventy bio	N/A	N/A	N/A	N/A	N/A

Latest TSVT, SYRE, CRMD, and PAHC Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
5/6/2025	PAHC Phibro Animal Health	quarterly	$0.12	2.52%	6/4/2025	6/4/2025	6/25/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CRMD CorMedix	N/A	4.21	3.99
PAHC Phibro Animal Health	2.67	2.91	1.23
SYRE Spyre Therapeutics	N/A	8.06	8.06
TSVT 2seventy bio	N/A	4.95	4.95

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CRMD CorMedix	34.18%
PAHC Phibro Animal Health	99.34%
SYRE Spyre Therapeutics	80.39%
TSVT 2seventy bio	93.90%

Insider Ownership

Company	Insider Ownership
CRMD CorMedix	5.30%
PAHC Phibro Animal Health	50.07%
SYRE Spyre Therapeutics	15.43%
TSVT 2seventy bio	7.20%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CRMD CorMedix	30	67.82 million	64.23 million	Optionable
PAHC Phibro Animal Health	1,940	40.53 million	20.24 million	Optionable
SYRE Spyre Therapeutics	73	60.28 million	50.98 million	Optionable
TSVT 2seventy bio	440	53.23 million	47.87 million	Optionable

TSVT, SYRE, CRMD, and PAHC Headlines

Recent News About These Companies

2seventy bio, Inc. (NASDAQ:TSVT) Shares Acquired by Western Standard LLC

May 22, 2025 | marketbeat.com

Stonepine Capital Management LLC Has $882,000 Stock Position in 2seventy bio, Inc. (NASDAQ:TSVT)

May 20, 2025 | marketbeat.com

2seventy bio Reports First Quarter Financial Results and Provides Update on Proposed Acquisition by Bristol Myers Squibb

May 7, 2025 | businesswire.com

2SEVENTY INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of 2seventy bio, Inc. - TSVT

April 16, 2025 | businesswire.com

2seventy Bio reports Q4 EPS (37c) vs ($1.11) last year

March 27, 2025 | markets.businessinsider.com

2seventy bio Reports Fourth Quarter and Full Year 2024 Financial Results

March 25, 2025 | businesswire.com

Jessica Snow Sells 2,298 Shares of 2seventy bio, Inc. (NASDAQ:TSVT) Stock

March 20, 2025 | insidertrades.com

2seventy bio, Inc. (TSVT) Upgraded to Buy: Here's Why

March 17, 2025 | zacks.com

2seventy Bio price target lowered to $5 from $6 at Morgan Stanley

March 14, 2025 | markets.businessinsider.com

2SEVENTY INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of 2seventy bio, Inc. - TSVT

March 14, 2025 | businesswire.com

2seventy bio, Inc. (NASDAQ:TSVT) Major Shareholder Sells $25,350,607.23 in Stock

March 14, 2025 | insidertrades.com

Biotech Stock Roundup: TSVT Up on BMY Deal, PTGX Up on Data & More

March 13, 2025 | msn.com

$HAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of 2seventy bio, Inc. - TSVT

March 12, 2025 | prnewswire.com

Shareholder Alert: The Ademi Firm investigates whether 2seventy bio, Inc. is obtaining a Fair Price for its Public Shareholders

March 11, 2025 | businesswire.com

2seventy bio accepts Bristol Myers’ takeover bid

March 11, 2025 | thepharmaletter.com

Biotech Stock 2seventy bio, Inc. (Nasdaq: TSVT) Soars on Acquisition News

March 11, 2025 | investorideas.com

TSVT Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of 2seventy bio, Inc. Is Fair to Shareholders

March 11, 2025 | tmcnet.com

2seventy Bio to be acquired by Bristol Myers for $5.00 per share in cash

March 11, 2025 | markets.businessinsider.com

TSVT Up on Acquisition Agreement With BMY for $286 Million

March 11, 2025 | zacks.com

ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of 2seventy bio, Inc.

March 11, 2025 | prnewswire.com

Bristol Myers buys out cell therapy partner 2seventy bio

March 11, 2025 | endpts.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

TSVT, SYRE, CRMD, and PAHC Company Descriptions

CorMedix NASDAQ:CRMD

$13.58 -0.36 (-2.58%)

Closing price 06/18/2025 04:00 PM Eastern

Extended Trading

$13.56 -0.02 (-0.11%)

As of 06/18/2025 07:59 PM Eastern

CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix Inc. was incorporated in 2006 and is based in Berkeley Heights, New Jersey.

Phibro Animal Health NASDAQ:PAHC

$23.96 -0.49 (-2.00%)

Closing price 06/18/2025 04:00 PM Eastern

Extended Trading

$23.98 +0.02 (+0.06%)

As of 06/18/2025 04:13 PM Eastern

Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Israel, Brazil, Ireland, and internationally. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets various products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs. It also offers animal health products, such as antibacterials, anticoccidials, nutritional specialty, and vaccines and vaccine adjuvants for animal's health and performance, food safety, and animal welfare; and engages in development, manufacturing, and marketing of microbial and bioproducts for various applications serving animal health and nutrition, environmental, industrial, and agricultural customers. In addition, the company develops, manufactures, and markets conventionally licensed and autogenous vaccine products, as well as adjuvants for animal vaccine manufacturers. Further, it provides formulations and concentrations of trace minerals, such as zinc, manganese, copper, iron, and other compounds to fortify the daily feed requirements of their livestock's diets and maintain optimal balance of trace elements in animals. Additionally, the company offers specialty ingredients for personal care, industrial chemical, and chemical catalyst industries. It sells its animal health and mineral nutrition products through local sales offices to integrated poultry, swine, and cattle producers, as well as through commercial animal feed manufacturers, wholesalers, and distributors. The company was formerly known as Philipp Brothers Chemicals, Inc. and changed its name to Phibro Animal Health Corporation in July 2003. Phibro Animal Health Corporation was founded in 1946 and is headquartered in Teaneck, New Jersey.

Spyre Therapeutics NASDAQ:SYRE

$15.08 -0.10 (-0.66%)

Closing price 06/18/2025 04:00 PM Eastern

Extended Trading

$15.06 -0.02 (-0.10%)

As of 06/18/2025 04:41 PM Eastern

Spyre Therapeutics, Inc., a preclinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease). The company is also developing SPY002, a human monoclonal antibody (mAb)candidates designed to bind to tumor necrosis factor-like ligand 1A; and SPY120, a combination of SPY001 (anti-a4ß7) and SPY002 (anti-TL1A) antibodies, which are in preclinical studies. In addition, its other early-stage programs include SPY003, an anti-IL-23 mAb; SPY004, a novel mechanism of action (MOA) mAb; SPY130, a combination of anti-a4ß7 and anti-IL-23 mAbs; and SPY230, a combination of anti-TL1A and anti-IL-23 mAbs. The company was formerly known as Aeglea BioTherapeutics, Inc. and changed its name to Spyre Therapeutics, Inc. in November 2023. Spyre Therapeutics, Inc. was incorporated in 2013 and is based in Waltham, Massachusetts.

2seventy bio NASDAQ:TSVT

$5.00 0.00 (0.00%)

As of 05/13/2025

2seventy bio, Inc., a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. The company's products pipeline includes Abecma, a chimeric antigen receptor T-cell product candidates for the treatment of multiple myeloma. It has a collaboration arrangement with Bristol Myers Squibb Company. The company was incorporated in 2021 and is headquartered in Cambridge, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time